ACST

Acasti Pharma Inc. Class A · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website acastipharma.com
Employees(FY) -
ISIN CA00430K8656

Performance

-2.54%

1W

-19.7%

1M

-18.48%

3M

+23.39%

6M

-6.92%

YTD

-10.35%

1Y

Profile

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Advanced Technical Analysis

Technical Analysis of ACST 2024-05-10

Overview:

In analyzing the technical indicators for ACST over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.

Trend Anal...

See more ...

Recent News & Updates

2024-03-24 03:54
12 Best Biotech Penny Stocks to Invest In(Insidermonkey)
2024-02-11 19:00
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2024-02-11 18:57
Acasti: Fiscal Q3 Earnings Snapshot(Yahoo Finance)
2024-01-31 19:00
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial(Globenewswire)
2023-12-12 19:00
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024(Globenewswire)
2023-11-12 19:20
Acasti: Fiscal Q2 Earnings Snapshot(Yahoo Finance)
2023-11-12 19:00
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights(Globenewswire)
2023-10-22 20:00
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial(Globenewswire)
2023-10-03 20:00
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)(Globenewswire)
2023-09-25 20:00
Acasti Announces $7.5 Million Private Placement Equity Financing(Yahoo Finance)
2023-09-05 20:00
Acasti to Participate in the H.C. Wainwright Global Investment Conference(Yahoo Finance)
2023-08-22 15:49
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)(Yahoo Finance)
2023-08-21 21:19
TEVA to Pay $250 Million to Settle Price-Fixing Charges(Yahoo Finance)
2023-08-10 19:10
Acasti: Fiscal Q1 Earnings Snapshot(Yahoo Finance)
2023-08-10 19:00
Acasti Announces First Quarter 2024 Financial Results and Business Highlights(Yahoo Finance)
2023-08-09 04:05
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting(Yahoo Finance)
2023-07-27 20:02
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates(Yahoo Finance)
2023-07-09 21:00
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients(Yahoo Finance)
2023-07-06 20:00
Acasti Pharma Announces 1-for-6 Reverse Stock Split(Yahoo Finance)
2023-07-04 21:00
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023(Yahoo Finance)
2023-06-22 19:00
Acasti Pharma Reports Fiscal Year 2023 Operational Results(Yahoo Finance)
2023-06-21 21:00
Acasti Announces Appointment of New Scientific Advisory Board Members(Yahoo Finance)
2023-05-16 21:00
Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference(Yahoo Finance)
2023-05-09 19:41
We're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely(Yahoo Finance)
2023-05-07 19:00
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025(Yahoo Finance)
2023-04-03 20:01
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND(Yahoo Finance)
2023-04-03 20:00
Acasti Announces Appointment of Prashant Kohli as CEO(Yahoo Finance)
2023-03-29 20:30
Acasti Pharma Inc. Announces the Resignation of a Director(Yahoo Finance)
2023-03-29 18:57
When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?(Yahoo Finance)
2023-03-12 20:00
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange(Yahoo Finance)

Page 1 of 4

previousnext